Dassault Systèmes to Buy Life Sciences Software Firm ArisGlobal for $1.8B

Dassault Systèmes to Buy ArisGlobal in a $1.8 Billion Life Sciences Play

French software group Dassault Systèmes has signed a definitive agreement to acquire ArisGlobal, a provider of AI-native compliance platforms for the life sciences industry, for about $1.8 billion in cash at closing. The deal also includes an additional payment of up to $200 million tied to multi-year revenue targets from artificial intelligence products. Dassault Systèmes' board approved the transaction unanimously, and the company says it will be funded entirely from cash on its balance sheet, preserving financial flexibility. Completion is expected in the second half of 2026, subject to regulatory approvals and customary closing conditions.

ArisGlobal's software spans regulatory affairs, pharmacovigilance (the monitoring of drug and medical device safety), quality management and medical affairs. The company says its platform is embedded in the critical processes of more than 200 clients, including half of the world's top 50 biopharmaceutical companies, as well as biotech and medtech firms, contract research organizations and international health authorities. ArisGlobal reports that its systems handle more than 12 million patient safety reports a year. The company employs more than 1,300 people and projects revenue of $175 million in 2026. Its NavaX AI platform, it says, delivers productivity gains of more than 30% in highly regulated environments.

For Dassault Systèmes — best known for its modeling and simulation software, which it has increasingly applied to research, clinical trials, production and quality in life sciences — the acquisition fills a missing piece: the regulated, post-approval side of the therapy lifecycle. The company's stated ambition is a unified data and intelligence platform that connects molecules, patients and outcomes, pairing its simulation expertise with ArisGlobal's real-world evidence. Dassault says the combination will allow life sciences customers to deploy clinical-grade AI at scale and bring safer therapies to market faster, and it expects the deal to add to revenue growth and earnings per share from the first year, citing ArisGlobal's margins.

Pascal Daloz, chief executive and chairman of Dassault Systèmes, said pairing real-world evidence with the group's modeling and simulation capabilities radically improves its ability to tackle current drug development challenges. Aman Wasan, ArisGlobal's chief executive, said the industry has long operated through fragmented systems and disconnected data environments, and that joining Dassault Systèmes advances the goal of an integrated, AI-first intelligence platform.

Why Dassault Is Paying $1.8 Billion for a Compliance Platform

Deal terms and company figures above are as reported by both companies. The following is analysis.

Why Compliance Software Is the Strategic Prize

Dassault Systèmes built its franchise on creating virtual worlds — digital models of physical products used to simulate performance before anything is built. In life sciences, that capability now covers research, clinical testing, manufacturing and quality. What the portfolio lacked was the regulated operational layer: pharmacovigilance, regulatory submissions, medical affairs and real-world evidence. ArisGlobal operates exactly there, in systems that life sciences companies cannot easily switch off or replace. The deal's logic is to connect those two ends — simulation on one side, real-world data on the other — into a single flow of information across the entire therapy lifecycle. If it works, it gives Dassault a positioning no smaller target could have provided.

The Price Tag and the Earn-Out's Message

At about $1.8 billion against ArisGlobal's projected 2026 revenue of $175 million, Dassault is paying roughly 10 times expected sales — or closer to 11 times if the full $200 million earn-out is achieved. That is a demanding but recognizable multiple for mission-critical software with recurring revenue and high margins; customers in regulatory workflows tend to be sticky. The more revealing detail is the earn-out itself: the additional $200 million is conditional on multi-year AI revenue targets. Dassault is structuring part of the price around proof that AI-led growth is real, and ArisGlobal's sellers are accepting that bet. The structure also gives investors a clear metric to track after closing.

The Main Risk Is Execution, Not Financing

Financially, the deal is conservative: it is cash-funded, and Dassault says it will be accretive to revenue and EPS from year one given ArisGlobal's margin profile. The operational question is harder. ArisGlobal's platform is mission-critical for clients in a heavily regulated industry — it processes over 12 million patient safety reports annually — and life sciences buyers are not known for tolerating disruption in compliance systems. The two companies will need to merge product roadmaps, data environments and corporate cultures while keeping regulators and customers confident. Any stumble in that integration would affect not only clients but also the AI revenue targets attached to the earn-out.

What the Deal Signals for Life Sciences Software

The acquisition is a marker of where spending in the sector is heading. ArisGlobal itself notes that software and AI will account for a growing share of compliance spending in life sciences. Regulatory-grade data platforms are scarce, deeply embedded and hard to displace, which is why they command premium prices and attract consolidators. For competitors in life sciences software, the deal raises the bar: any rival that wants to own the full therapy lifecycle will now have to match a combined Dassault–ArisGlobal offering that spans both simulation and regulated operations. A note of caution: the grander claims — clinical-grade AI at scale, dramatically faster patient outcomes — remain promises until the platforms are genuinely integrated and validated in real deployments.

What to Watch Between Now and the Deal's Close

The deal will not close until the second half of 2026, and its impact will unfold over years. Until then, the relevant players have specific things to watch.

• For Dassault Systèmes investors: track completion of regulatory approvals in H2 2026 and, after closing, whether ArisGlobal delivers on its projected $175 million in 2026 revenue and hits the multi-year AI revenue targets that trigger the up-to-$200 million earn-out. The company expects the deal to be accretive to revenue growth and EPS from year one, financed from existing cash.
• For ArisGlobal's 200-plus clients: no changes are expected before closing, but customers using the platform for pharmacovigilance, regulatory affairs or quality should watch for the combined product roadmap and how Dassault's simulation tools integrate with NavaX AI. Safety reporting and compliance workflows — the platform handles over 12 million reports a year — should be raised in customer conversations early if transition concerns emerge.
• For life sciences and medtech companies evaluating compliance software: the deal signals that AI-native, regulation-grade platforms are becoming strategic assets. When comparing vendors, ask how AI tools are validated in regulated environments and how data is governed across the therapy lifecycle — the two capabilities Dassault and ArisGlobal are betting their earn-out on.
• A number worth testing: ArisGlobal claims NavaX AI delivers productivity gains above 30% in highly regulated settings. Buyers negotiating with any vendor should press for documented evidence of that kind of figure, since it now underpins the financial logic of this acquisition.